Ranbaxy (UK) Ltd has launched esomeprazole tablets in strengths of 20 mg and 40 mg, in the UK
Ranbaxy Laboratories today said it has launched generic esomeprazol tablets, used for treating ulcers, in the United Kingdom (UK).
Ranbaxy (UK) Ltd, a wholly owned subsidiary of Ranbaxy Laboratories Ltd, has launched esomeprazole tablets in strengths of 20 mg and 40 mg, in the UK, the company said in a statement.
Esomeprazole is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome.
Ranbaxy's product is the first approved generic bio-equivalent version of AstraZeneca's 'Nexium' in the UK market. According to IMS June 2011 data, esomeprazol tablets had sales of 60 million pounds in that country, the statement added.
Commenting on the development Ranbaxy Europe Regional Director Debashis Dasgupta said: "We are committed to bringing high quality, affordable medicines for the benefit of patients and healthcare systems worldwide and in Europe. The introduction of esomeprazole in the UK, is an important and significant step in this direction."
The company would offer the product through pharmacies, retail and wholesale stores with immediate effect.
In the late afternoon, Ranbaxy was trading at around Rs478.15 per share on the Bombay Stock Exchange, 0.05% down from the previous close.
BHEL will set up the Raw Material Handling System package for NMDC’s three million tonnes per annum steel plant at Nagarnar in Chhattisgarh, on a turnkey basis
BHEL has bagged a Rs1,395-crore contract from the country's biggest miner NMDC for handling raw materials at its steel plant at Nagarnar in Chhattisgarh.
BHEL will set up the Raw Material Handling System (RMHS) package for NMDC's three million tonnes per annum steel plant at Nagarnar in Chhattisgarh, on a turnkey basis, the power equipment maker said in a statement today.
The contract was signed in the presence of BHEL CMD, BP Rao, and the NMDC CMD, Rana Som.
The project includes engineering, procurement and construction of complete RMHS, from receipt of various raw materials (coal, iron ore etc) from wagon tippling to crushing. The order envisages installation of conveyor length of about 30km.
The Government has recently approved disinvestment of 5% of its stake in BHEL, which could fetch about Rs4,320 crore. It holds 67.72% in BHEL.
In 2010-11, the company recorded a turnover of Rs43,337 crore and a profit after tax of Rs6,011 crore.
In the late afternoon, BHEL was trading at around Rs1,714.05 per share on the Bombay Stock Exchange, 1.32% down from the previous close.
Multicare will market Sanofi-Aventis’s central nervous system global brands, Solian (Amisulpride) and Stilnox (Zolpidem Hemitartrate) in the Philippines
Sanofi-Aventis Philippines Inc, which is part of the Sanofi Group, and Multicare Pharmaceuticals, the Philippines subsidiary of Lupin Ltd, have entered into a marketing and distribution agreement whereby Multicare will market Sanofi-Aventis's central nervous system global brands, Solian (Amisulpride) and Stilnox (Zolpidem Hemitartrate) in the Philippines. The annual sales revenues of these brands are valued at PHP 138 million (IMS).
Solian is the third largest selling atypical anti-psychotic agent in the Philippines. It is indicated for acute and chronic schizophrenia characterised by both negative and positive symptoms. Stilnox is the second largest selling drug for insomnia and sleep disorders in the country. The agreement will enable Sanofi-Aventis to capitalise on Multicare's CNS marketing reach and expertise. Multicare will focus on bringing these brands into a higher growth path.